Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Revance Therapeutics ( NASDAQ:RVNC – Free Report ) in a report published on Thursday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on the company. Mizuho decreased their price target on Revance Therapeutics from $6.66 to $3.



10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Finally, Barclays lowered their price target on shares of Revance Therapeutics from $7.

00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday, December 23rd. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock.

According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.39.

Read Our Latest Stock Analysis on RVNC Revance Therapeutics Stock Performance Institutional Inflows and Outflows A number of institutional investors have recently bought and sold shares of RVNC. CIBRA Capital Ltd bought a new position in shares of Revance Therapeutics during the fourth quarter worth $3,466,000. Alpine Global Management LLC bought a new position in Revance Therapeutics during the fourth quarter worth about $37,000.

Two Sigma Investments LP grew its stake in Revance Therapeutics by 8.6% in the fourth quarter. Two Sigma Investments LP now owns 170,136 shares of the biopharmaceutical company’s stock valued at $517,000 after acquiring an additional 13,539 shares during the period.

ProShare Advisors LLC grew its stake in Revance Therapeutics by 19.3% in the fourth quarter. ProShare Advisors LLC now owns 75,252 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 12,155 shares during the period.

Finally, Man Group plc increased its holdings in shares of Revance Therapeutics by 47.8% in the fourth quarter. Man Group plc now owns 443,544 shares of the biopharmaceutical company’s stock worth $1,348,000 after acquiring an additional 143,544 shares in the last quarter.

Institutional investors and hedge funds own 97.70% of the company’s stock. About Revance Therapeutics ( Get Free Report ) Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.

The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. Further Reading Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .

.